You are here

Article Text

Article menu
Download PDFPDF
Prognosis
Predictors of symptomatic remission in people with schizophrenia identified

http://dx.doi.org/10.1136/ebmh.10.3.73

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006;67:1690–7.OpenUrlPubMed

    Q What are the predictors of remission in outpatients with schizophrenia?

    METHOD

    Embedded ImageDesign:

    Prospective cohort study.

    Embedded ImageSetting:

    European Schizophrenia Outpatient Health Outcomes study, Germany; recruitment January to December 2001.

    Embedded ImagePopulation:

    2960 adult outpatients with DSM-IV schizophrenia either switching to or beginning a new antipsychotic (mean age 42 years; 49% male). Exclusions: IQ ⩽70, other DSM-IV schizophrenia spectrum disorders, bipolar I disorder, or psychotic disorder.

    Embedded ImagePrognostic factors:

    Baseline predictors: age; gender; illness duration; symptoms (Clinical Global Impressions-Severity of Illness (CGI)-Schizophrenia scale overall severity score subscale scores). Functional predictors included occupational status, independent living and subjective wellbeing (Subjective Wellbeing Under Neuroleptic Treatment Scale (SWN-K)). Antipsychotic treatment factors included first antipsychotic, neurological side effects, and …

    View Full Text

    Footnotes

    • For correspondence: Martin Lambert, MD, Psychosis Early Detection and Intervention Centre, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Center Hamberg-Eppendorf, Martinistr 52, 20246 Hamburg, Germany; lambert{at}uke.uni-hamburg.de

    • Source of funding: Lilly Deutschland GmbH.

    Footnotes

    • Competing interests: Dr McIntyre is a Consultant and Speaker for Astra-Zeneca, Eli Lilly, Janssen-Ortho, Organon, Wyeth, Lundbeck, GSK, Oryx, Biovail, Pfizer, Prestwick, BMS, and Shire; and has received research funding from Wyeth, GSK, Merck, Servier and Astra-Zeneca and Miss Soczynska received travel funds from Organon, Janssen Ortho.